SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Open Access
- 26 September 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (2) , 778-785
Abstract
SHP-2 phosphatase forms a stable protein complex with and is heavily tyrosine-phosphorylated by the oncogenic tyrosine kinase Bcr-Abl. However, the role of SHP-2 in Bcr-Abl–mediated leukemogenesis is unclear. In the present report, we provide evidence that SHP-2 is required for hematopoietic cell transformation by Bcr-Abl. In vitro biological effects of Bcr-Abl transduction were diminished in SHP-2Δ/Δ hematopoietic cells, and the leukemic potential of Bcr-Abl–transduced SHP-2Δ/Δ cells in recipient animals was compromised. Further analyses showed that Bcr-Abl protein (p210) was degraded, and its oncogenic signaling was greatly decreased in SHP-2Δ/Δ cells. Treatment with proteasome inhibitors or reintroduction of SHP-2 restored p210 level in Bcr-Abl–transduced SHP-2Δ/Δ cells. Subsequent investigation revealed that SHP-2 interacted with heat shock protein 90, an important chaperone protein protecting p210 from proteasome-mediated degradation. The role of SHP-2 in the stability of p210 is independent of its catalytic activity. Blockade of SHP-2 expression in p210-expressing cells by antisense or small-interfering RNA approaches decreased p210 level, causing cell death. Inhibition of SHP-2 enzymatic activity by overexpression of catalytically inactive SHP-2 mutant did not destabilize p210 but enhanced serum starvation-induced apoptosis, suggesting that SHP-2 also plays an important role in downstream signaling of p210 kinase. These studies identified a novel function of SHP-2 and suggest that SHP-2 might be a useful target for controlling Bcr-Abl–positive leukemias.Keywords
This publication has 59 references indexed in Scilit:
- Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous LeukemiaCancer Research, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- c-CBL is not required for leukemia induction by Bcr-Abl in miceOncogene, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeuticsCancer Cell, 2002
- Autoinhibition of c-AblCell, 2002
- BCR/ABL induces multiple abnormalities of cytoskeletal function.Journal of Clinical Investigation, 1997
- Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitroScience, 1992
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Reduced Incidence of Persistent Chromosome Aberrations in Mice Irradiated at Low Dose RatesScience, 1963